Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

Julie R. Park*, Judith G. Villablanca, Barbara Hero, Brian H. Kushner, Keith Wheatley, Klaus H. Beiske, Ruth L. Ladenstein, Sylvain Baruchel, Margaret E. Macy, Lucas Moreno, Nita L. Seibel, Andrew D. Pearson, Katherine K. Matthay, Dominique Valteau-Couanet

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting'. Together they form a unique fingerprint.

Medicine & Life Sciences